^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ASP1951

    i
    Other names: ASP1951, PTZ-522
    Associations

    News

    Trials
    Company:
    Astellas
    Drug class:
    GITR agonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    KEYNOTE-B02: A Study of ASP1951 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=119, Terminated, Astellas Pharma Global Development, Inc. | Completed --> Terminated; Study was terminated for lack of efficacy.
    Trial termination • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • ASP1951
    almost2years
    KEYNOTE-B02: A Study of ASP1951 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1; Phase classification: P1b --> P1
    Phase classification
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • ASP1951
    over2years
    KEYNOTE KN-B02: A Study of ASP1951 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b; Active, not recruiting --> Completed
    Combination therapy • Trial completion • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • ASP1951
    over3years
    KEYNOTE KN-B02: A Study of ASP1951 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b; Trial completion date: Mar 2024 --> Dec 2023 | Trial primary completion date: Mar 2024 --> Dec 2023
    Combination therapy • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • ASP1951
    over3years
    KEYNOTE KN-B02: A Study of ASP1951 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b; Recruiting --> Active, not recruiting | N=435 --> 120
    Combination therapy • Enrollment change • Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • ASP1951
    over4years
    KEYNOTE KN-B02: A Study of ASP1951 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=435, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Oct 2023 --> Apr 2024 | Trial primary completion date: Oct 2023 --> Apr 2024
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP1951
    over5years
    KEYNOTE KN-B02: A Study of ASP1951 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=435, Recruiting, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP1951